Prognostic value of galectin-3 in primary cutaneous melanoma

Journal of the European Academy of Dermatology and Venereology

Volumn 25, Issue 10, 2011, Pages 1174-1181

  Buljan, M ^a,c   Situm M ^a,c   Tomas, D ^a,b   Milosevic M ^b   Kruslin B ^a,b  

^a SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

^c UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

galectin 3; melanoma

Indexed keywords

GALECTIN 3;

ADOLESCENT; ADULT; AGED; ARM; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEG; LYMPH NODE METASTASIS; LYMPH VESSEL; MAJOR CLINICAL STUDY; MALE; MELANOMA; MITOSIS RATE; PREDICTION; PRIMARY CUTANEOUS MELANOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; SKIN NODULE; SKIN ULCER; TRUNK; TUMOR LOCALIZATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GALECTIN 3; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SKIN NEOPLASMS; YOUNG ADULT;

EID: 80053021402     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2010.03943.x     Document Type: Article

References (40)

1. Rubin KM, Lawrence DP,. Your patient with melanoma: staging, prognosis, and treatment. Oncology (Williston Park) 2009; 23 (8 Suppl.): 13-21.
2. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19: 3622-3634.
3. Zubieta MR, Furman D, Barrio M, et al. Galectin-3 expression correlates with apoptosis of tumor-associated lymphocytes in human melanoma biopsies. Am J Pathol 2006; 168: 1666-1675.
4. Nangia-Makker P, Nakahara S, Hogan V, et al. Galectin-3 in apoptosis, a novel therapeutic target. J Bioenerg Biomembr 2007; 39: 79-84.
5. Liu FT, Rabinovich GA,. Galectins as modulators of tumour progression. Nat Rev Cancer 2005; 5: 29-41.
6. Sakaki M, Fukumori T, Fukawa T, et al. Clinical significance of Galectin-3 in clear cell renal cell carcinoma. J Med Invest 2010; 57: 152-157.
7. Nakahara S, Oka N, Raz A,. On the role of galectin-3 in cancer apoptosis. Apoptosis 2005; 10: 267-275.
8. de Melo FH, Butera D, Medeiros RS, et al. Biological applications of a chimeric probe for the assessment of galectin-3 ligands. J Histochem Cytochem 2007; 55: 1015-1026.
9. Davidson PJ, Davis MJ, Patterson RJ, et al. Shuttling of galectin-3 between the nucleus and cytoplasm. Glycobiology 2002; 12: 329-337.
10. Eude-Le Parco I, Gendronneau G, Dang T, et al. Genetic assessment of the importance of galectin-3 in cancer initiation, progression, and dissemination in mice. Glycobiology 2009; 19: 68-75.
11. Liu TY, Chen CY, Tien HF, et al. Loss of CD7, independent of galectin-3 expression, implies a worse prognosis in adult T-cell leukaemia/lymphoma. Histopathology 2009; 54: 214-220.
12. Deutscher SL, Figueroa SD, Kumar SR,. Tumor targeting and SPECT imaging properties of an (111)In-labeled galectin-3 binding peptide in prostate carcinoma. Nucl Med Biol 2009; 36: 137-146.
13. Bartolazzi A, D'Alessandria C, Parisella MG, et al. Thyroid cancer imaging in vivo by targeting the anti-apoptotic molecule galectin-3. PLoS One 2008; 3: 3768.
14. Chiu CG, Strugnell SS, Griffith OL, et al. Diagnostic utility of galectin-3 in thyroid cancer. Am J Pathol 2010; 176: 2067-2081.
15. Song S, Mazurek N, Liu C, et al. Galectin-3 mediates nuclear beta-catenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3beta activity. Cancer Res 2009; 69: 1343-1349.
16. Yoo BC, Hong SH, Ku JL, et al. Galectin-3 stabilizes heterogeneous nuclear ribonucleoprotein Q to maintain proliferation of human colon cancer cells. Cell Mol Life Sci 2009; 66: 350-364.
17. Canesin G, Gonzalez-Peramato P, Palou J, et al. Galectin-3 expression is associated with bladder cancer progression and clinical outcome. Tumour Biol 2010; 31: 277 -285.
18. Li W, Jian-jun W, Xue-Feng Z, et al. CD133(+) human pulmonary adenocarcinoma cells induce apoptosis of CD8(+) T cells by highly expressed galectin-3. Clin Invest Med 2010; 33: 44-53.
19. Van den Brule FA, Buicu C, Berchuck A, et al. Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. Hum Pathol 1996; 27: 1185-1191.
20. Van den Brule FA, Fernandez PL, Buicu C, et al. Differential expression of galectin-1 and galectin-3 during first trimester human embryogenesis. Dev Dyn 1997; 209: 399-405.
21. Castronovo V, Van Den Brule FA, Jackers P, et al. Decreased expression of galectin-3 is associated with progression of human breast cancer. J Pathol 1996; 179: 43-48.
22. Kapucuoglu N, Basak PY, Bircan S, et al. Immunohistochemical galectin-3 expression in non-melanoma skin cancers. Pathol Res Pract 2009; 205: 97-103.
23. Mollenhauer J, Deichmann M, Helmke B, et al. Frequent downregulation of DMBT1 and galectin-3 in epithelial skin cancer. Int J Cancer 2003; 105: 149-157.
24. Castronovo V, Liu FT, van den Brule FA,. Decreased expression of galectin-3 in basal cell carcinoma of the skin. Int J Oncol 1999; 15: 67-70.
25. Iurisci I, Tinari N, Natoli C, et al. Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin Cancer Res 2000; 6: 1389-1393.
26. Vereecken P, Debray C, Petein M, et al. Expression of galectin-3 in primary and metastatic melanoma: immunohistochemical studies on human lesions and nude mice xenograft tumors. Arch Dermatol Res 2005; 296: 353-358.
27. Mourad-Zeidan AA, Melnikova VO, Wang H, et al. Expression profiling of Galectin-3-depleted melanoma cells reveals its major role in melanoma cell plasticity and vasculogenic mimicry. Am J Pathol 2008; 173: 1839-1852.
28. Prieto VG, Mourad-Zeidan AA, Melnikova V, et al. Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma. Clin Cancer Res 2006; 12: 6709-6715.
29. Van den Brule FA, Liu FT, Castronovo V,. Transglutaminase-mediated oligomerization of galectin-3 modulates human melanoma cell interactions with laminin. Cell Adhes Commun 1998; 5: 425-435.
30. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-3648.
31. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-6206.
32. Vereecken P, Zouaoui Boudjeltia K, Debray C, et al. High serum galectin-3 in advanced melanoma: preliminary results. Clin Exp Dermatol 2006; 31: 105-109.
33. Califice S, Castronovo V, Van Den Brule F,. Galectin-3 and cancer (Review). Int J Oncol 2004; 25: 983-992.
34. Vereecken P, Awada A, Suciu S, et al. Evaluation of the prognostic significance of serum galectin-3 in American Joint Committee on Cancer stage III and stage IV melanoma patients. Melanoma Res 2009; 19: 316-320.
35. Fukumori T, Kanayama HO, Raz A,. The role of galectin-3 in cancer drug resistance. Drug Resist Updat 2007; 10: 101-108.
36. Akahani S, Nangia-Makker P, Inohara H, et al. Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res 1997; 57: 5272-5276.
37. Yoshii T, Fukumori T, Honjo Y, et al. Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. J Biol Chem 2002; 277: 6852-6857.
38. Takenaka Y, Fukumori T, Yoshii T, et al. Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic activity in response to chemotherapeutic drugs. Mol Cell Biol 2004; 24: 4395-4406.
39. Fukumori T, Oka N, Takenaka Y, et al. Galectin-3 regulates mitochondrial stability and antiapoptotic function in response to anticancer drug in prostate cancer. Cancer Res 2006; 66: 3114-3119.
40. Bogoeva VP, Varriale A, John CM, et al. Human galectin-3 interacts with two anticancer drugs. Proteomics 2010; 10: 1946-1953.